Dedicated facilities for manufacturing of viral vectors

Image1Strasbourg site, France

  • 20+ year track record of supplying gene therapy clinical material , Opening inspection in 1995
  • Process and analytical method development 
  • 3 levels 4900 m2, 3 manufacturing suites (BSL2)
  • DS in cell stacks < 60 m2 or Rollerbottles < 17 m2
  • Aseptic fill and finish (grade A rigid isolator/ DP < 10,000 liquid fills vials per batch)
  • QC release and stability testing 
  • QC site : 400 m2 of laboratories (BSL2)
  • 2021 FDA PAI readiness program

ABL-Europe-site-LyonLyon site, France

  • Site acquired by ABL Europe in June 2018
  • Modern facility built in 2013. Opening inspection 2014
  • 3 x 200 L SUB GMP suites / Cell stacks (40 m2)
  • 1st 200 L GMP suite operational Q1 2019. Suite 2 & 3 in 2020 / 2021
  • Process development & analytical support labs
  • Process transfer / optimisation & scale-up to 200 L
  • Performing phase 1 – 3 GMP supply
  • Mirror viral vector bioprocessing capabilities across all sites